SCHEMBL21725473

SCHEMBL21725473

CC(C)c1ccc(Cl)cc1N(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
GAA P10253 1/20 0.47
HTT P42858 2/20 0.44
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
MAPK1 P28482 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
POLB P06746 1/20 0.38
BLM P54132 1/20 0.38
ALDH1A1 P00352 1/20 0.38
FSCN1 Q16658 1/20 0.35
KCNH2 Q12809 2/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
TRPA1 O75762 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12404707 0.83 KMT2A (0.52) KMT2AGAAHTTLMNATP53
SCHEMBL23251386 0.81 KMT2A (0.42) KMT2AGAAHTTLMNATP53
SCHEMBL20073675 0.78 HTT (0.42) KMT2AHTTLMNATP53ALDH1A1
SCHEMBL20285948 0.77 TRPA1 (0.52) LMNAALDH1A1CYP1A2TRPA1CHRM1
SCHEMBL7537241 0.77 LMNA (0.39) GAAHTTLMNAGABRA1ALDH1A1
SCHEMBL24497524 0.76 PSEN1 (0.40) ALDH1A1
SCHEMBL21756916 0.75 GABRA1 (0.39) LMNAGABRA1GABRB1ALDH1A1TRPA1
SCHEMBL20346962 0.75 HRH4 (0.37) LMNAALDH1A1KCNH2CYP1A2TRPA1
SCHEMBL3789565 0.75 GAA (0.61) KMT2AGAALMNATP53MAPK1
SCHEMBL12197660 0.75 GABRA1 (0.52) KMT2AHTTLMNATP53GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-01-07 US disclosed
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-09-08 US disclosed
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-07-09 US disclosed
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885HTT 836/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885HTT 836/4885
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885HTT 836/4885
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885HTT 836/4885
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885HTT 836/4885
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885HTT 836/4885
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885HTT 836/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R KMT2A 1341/4885GAA 2646/4885HTT 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.